Valganciclovir + Ganciclovir
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Allogeneic Stem Cell Transplantation
Conditions
Allogeneic Stem Cell Transplantation
Trial Timeline
Sep 1, 2010 → —
NCT ID
NCT01185223About Valganciclovir + Ganciclovir
Valganciclovir + Ganciclovir is a phase 3 stage product being developed by Roche for Allogeneic Stem Cell Transplantation. The current trial status is terminated. This product is registered under clinical trial identifier NCT01185223. Target conditions include Allogeneic Stem Cell Transplantation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01185223 | Phase 3 | Terminated |
| NCT00002377 | Phase 3 | Completed |
Competing Products
9 competing products in Allogeneic Stem Cell Transplantation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ASP0113 | Astellas Pharma | Phase 2 | 52 |
| Blinatumomab in combination with donor lymphocyte infusion | Amgen | Phase 2 | 51 |
| Denosumab | Amgen | Phase 2 | 51 |
| DTaP-IPV-HBV/Hib combination vaccine, Infanrix hexa + heptavalent pneumococcal conjugate vaccine, Prevenar | Pfizer | Phase 3 | 76 |
| Inotuzumab Ozogamicin + Vincristine Sulfate Liposome | Pfizer | Phase 1/2 | 40 |
| Genotropin (Recombinant Human Growth Hormone) | Pfizer | Phase 1 | 32 |
| immunosuppression | Pfizer | Phase 2 | 51 |
| Mycophenolate Mofetil | Hikma Pharmaceuticals | Pre-clinical | 18 |
| Vancomycin Pre-Treatment + Vancomycin Placebo + SER-155 + SER-155 Placebo | Seres Therapeutics | Phase 1 | 25 |